Our Pipeline

---

 ViroCarb has developed a groundbreaking proprietary class of antiviral drug candidates in collaboration with leading academics from various Canadian universities, resulting from over 12 years of research. 

The rapid evolution of viruses often leads to resistance against current drugs that target viral components. Our host-directed approach, however, impedes the replication of multiple viruses without producing drug resistance, as viral changes do not affect the sensitivity of our drugs. Our small molecule pipeline targets a cellular process essential for the replication of various viruses, specifically RNA processing. This strategy not only proves effective against a wide range of viruses but also establishes a more substantial barrier against the development of resistance, addressing the growing need for preparedness against potential future pandemics.

We have selected our preclinical drug candidate, GPS543, due to its potent antiviral activity against multiple viruses, including major respiratory pathogens like coronaviruses, adenoviruses, and influenza viruses. It demonstrates an excellent selectivity index, indicating its effectiveness and safety in human cell cultures. Our studies show that this drug has a significantly lower likelihood of inducing drug resistance compared to existing approved treatments. Additionally, it exhibits high oral bioavailability and excellent pharmacokinetic properties, with no toxicity observed in repeated escalating doses tested in mice.

We plan to advance this candidate to clinical trials aimed at treating major respiratory viral infections and preparing for future viral pandemics.